Silence Therapeutics plc
SLNCF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$929.09M
Close$
$0.35
94.4% downside
Current Fair Value
94.4% downsideOvervalued by 94.4% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $929.09 Million |
|---|---|
| Enterprise Value | $856.93 Million |
| Earnings per Share | $-0.63 |
| Beta | 1.41 |
| Outstanding Shares | 141,709,762 |
Return
| Return on Equity | -101.36% |
|---|---|
| Return on Assets | -36.65% |
| Return on Invested Capital | -80.87% |
Valuation & Multiples
| P/E Ratio | -2.59 |
|---|---|
| PEG | 4.69 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 1393.38 |
| Enterprise Value to EBIT | -11.31 |
| Enterprise Value to Net Income | -22 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 10, 2026
EPS Estimate
$-0.07
Consensus analyst estimateRevenue Estimate
$1.66 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Silence Therapeutics Plc
74 employees
CEO: David Solomon
Silence Therapeutics plc, a biotechnology firm headquartered in London, United Kingdom, is dedicated to the discovery and advancement of pioneering ribonucleic acid (RNA) therapeutics. Its research and development efforts span key areas ...